BRPI0410694A - compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina - Google Patents

compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina

Info

Publication number
BRPI0410694A
BRPI0410694A BRPI0410694-6A BRPI0410694A BRPI0410694A BR PI0410694 A BRPI0410694 A BR PI0410694A BR PI0410694 A BRPI0410694 A BR PI0410694A BR PI0410694 A BRPI0410694 A BR PI0410694A
Authority
BR
Brazil
Prior art keywords
piperazine
compounds
tetra
penta
derived ring
Prior art date
Application number
BRPI0410694-6A
Other languages
English (en)
Inventor
Shubh D Sharma
Yi-Qun Shi
Zhijun Wu
Ramesh Rajpurohit
Annette M Shadiack
Papireddy Purma
Kevin D Burris
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of BRPI0410694A publication Critical patent/BRPI0410694A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE PIPERAZINA TETRA E PENTA-SUBSTITUìDOS E DE ANEL DERIVADO DE PIPERAZINA". Composto receptor-específico de melanocortina da fórmula geral de estrutura (I) onde X, R~ 1~, R~ 2a~, R~ 2b~, R~ 3~, R~ 4a~, R~ 4b~, R~ 5~, e R~ 5b~ são conforme definido na especificação, composto que se liga com alta afinidade a um ou mais receptores de melanocortina e que é opcionalmente um agonista, um antagonista, um agonista inverso ou um antagonista de um agonista inverso, e que pode ser empregado para tratamento de condições ou distúrbios associados com receptor de melanocortina e métodos para o uso dos compostos da invenção.
BRPI0410694-6A 2003-05-01 2004-05-03 compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina BRPI0410694A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46744203P 2003-05-01 2003-05-01
US54639304P 2004-02-19 2004-02-19
US10/837,519 US7456184B2 (en) 2003-05-01 2004-04-30 Melanocortin receptor-specific compounds
PCT/US2004/013803 WO2004098602A1 (en) 2003-05-01 2004-05-03 Melanocortin receptor-specific compounds

Publications (1)

Publication Number Publication Date
BRPI0410694A true BRPI0410694A (pt) 2006-06-20

Family

ID=33425190

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410694-6A BRPI0410694A (pt) 2003-05-01 2004-05-03 compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina

Country Status (10)

Country Link
US (2) US7456184B2 (pt)
EP (1) EP1622618A4 (pt)
JP (1) JP2006525369A (pt)
KR (1) KR20060009285A (pt)
AU (1) AU2004235792A1 (pt)
BR (1) BRPI0410694A (pt)
CO (1) CO5700752A2 (pt)
EA (1) EA012502B1 (pt)
MX (1) MXPA05011729A (pt)
WO (1) WO2004098602A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
DK1805158T3 (en) * 2004-10-29 2018-08-06 Kalypsys Inc SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
JP2009504671A (ja) * 2005-08-11 2009-02-05 パラティン テクノロジーズ， インコーポレイテッド ジアミン基を備えるメラノコルチン受容体特異的ピペラジン化合物
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
JP5322650B2 (ja) * 2005-10-25 2013-10-23 カリプシス・インコーポレーテッド Ｐｐａｒ調節剤の塩および代謝障害の治療方法
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
ATE539762T1 (de) * 2006-03-30 2012-01-15 Palatin Technologies Inc Aminosäureersatz für peptidkonstruktionen
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
AR060937A1 (es) * 2006-05-16 2008-07-23 Kalypsys Inc Compuestos biciclicos sustituidos con sulfonilo como moduladores de ppar
WO2008017852A1 (en) * 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CA2664245A1 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
US20090081197A1 (en) * 2007-06-01 2009-03-26 Palatin Technologies, Inc. Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity
WO2009144432A1 (en) * 2008-05-30 2009-12-03 Palatin Technologies, Inc. Mc4-r agonists for the treatment of obesity
WO2010065801A1 (en) * 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CA2995188A1 (en) * 2015-08-04 2017-02-09 Astellas Pharma Inc. Piperazine derivative
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JPWO2024075813A1 (pt) * 2022-10-07 2024-04-11

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4711957A (en) * 1979-07-13 1987-12-08 The B. F. Goodrich Company Synthesis of 2-keto-1,4-diazacycloalkanes
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
US4968684A (en) * 1987-04-01 1990-11-06 Janssen Pharmaceutica N.V. Method of improving sleep
KR900018073A (ko) * 1988-05-23 1990-12-20 추후보충 피페라진 화합물
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
US5334830A (en) * 1991-05-29 1994-08-02 Olympus Optical Co., Ltd. Scanning optical microscope having a compact confocal optical system for adjusting position of aperture
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
AU679053B2 (en) * 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
HUT70045A (en) * 1993-06-17 1995-09-28 Takeda Chemical Industries Ltd 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them
JPH09500109A (ja) * 1993-06-18 1997-01-07 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白質トランスフェラーゼの阻害剤
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753445A (en) * 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
US5599809A (en) * 1994-09-29 1997-02-04 Merck & Co., Inc. Method for improving reproductive efficiency in farm animals
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2217006C (en) * 1995-04-13 2001-05-22 Hoechst Marion Roussel, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
EP0822931B1 (en) * 1995-04-26 2002-03-27 Takeda Chemical Industries, Ltd. Piperazinones useful as inhibitors of platelet aggregation
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
ATE288444T1 (de) * 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP9901037A3 (en) * 1995-12-18 2001-11-28 Fujisawa Pharmaceutical Co Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
US6239154B1 (en) * 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
GB9612276D0 (en) * 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
EP0852117A4 (en) * 1996-06-12 1999-02-03 Kyowa Hakko Kogyo Kk IMPROVEMENT OF LIPID METABOLISM
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
US5965565A (en) 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
CA2275478A1 (en) * 1996-12-17 1998-06-25 Kentaro Sato Piperazine compounds as inhibitors of mmp or tnf
ES2158611T3 (es) * 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
CA2287397A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
WO1998053869A1 (en) 1997-05-27 1998-12-03 Direct-Haler A/S Inhaler for powdered medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
US6287587B2 (en) * 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6211626B1 (en) * 1997-08-26 2001-04-03 Color Kinetics, Incorporated Illumination components
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US5892038A (en) * 1997-12-08 1999-04-06 Pharmacopeia, Inc. Hydroxy-amino acid amides
US6084098A (en) * 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
EP1076644B1 (en) * 1998-04-29 2004-06-23 Ortho-McNeil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
FR2780649B1 (fr) * 1998-07-06 2001-03-09 Univ Paris Vii Denis Diderot Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
WO2000005373A2 (en) 1998-07-21 2000-02-03 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
US6169006B1 (en) * 1998-07-29 2001-01-02 Advanced Micro Devices, Inc. Semiconductor device having grown oxide spacers and method of manufacture thereof
JP3623448B2 (ja) * 1998-08-12 2005-02-23 ファイザー・プロダクツ・インク Ｔａｃｅインヒビター
US6372747B1 (en) * 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6800636B2 (en) * 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
US6432959B1 (en) * 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
US6294539B1 (en) * 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
MXPA01008849A (es) * 1999-03-03 2003-07-21 Optinose As Dispositivo de administracion nasal.
US6033656A (en) * 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
JP2003505435A (ja) * 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU6621600A (en) 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
EP1214409B1 (en) 1999-09-08 2006-05-17 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6515122B1 (en) 1999-09-24 2003-02-04 Lion Bioscience Ag Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US20030064921A1 (en) * 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE19963234A1 (de) * 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6462046B2 (en) * 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
KR20020075396A (ko) 2000-01-28 2002-10-04 멜라큐어 테라퓨틱스 에이비 신규의 멜라노코르틴 수용체 효능제 및 길항제
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001070347A1 (en) 2000-03-17 2001-09-27 Fit Express, Inc. Golf swing conditioner
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
AU2001249296B2 (en) * 2000-03-23 2005-03-24 Merck Sharp & Dohme Corp. Substituted piperidines as melanocortin receptor agonists
US6472398B1 (en) * 2000-03-23 2002-10-29 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
PL358618A1 (pl) * 2000-03-31 2004-08-09 Pfizer Products Inc. Nowe pochodne piperazyny
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
NZ523800A (en) 2000-06-27 2005-02-25 Taisho Pharmaceutical Co Ltd Therapeutic preparation comprising a melanocortin receptor (MC4) antagonist or a piperazine derivative thereof for treating anxiety neurosis or depression
CA2412563A1 (en) 2000-06-28 2002-01-03 Pfizer Products Inc. Melanocortin receptor ligands
JP2004516239A (ja) * 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
JP2002056510A (ja) * 2000-08-07 2002-02-22 Matsushita Electric Ind Co Ltd シールド型磁気ヘッド並びに磁気再生装置
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
KR100483300B1 (ko) * 2000-08-30 2005-04-15 에프. 호프만-라 로슈 아게 선택적 환형 펩타이드
US20020183316A1 (en) * 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
KR100394083B1 (ko) * 2000-12-04 2003-08-06 학교법인 성신학원 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법
US6612805B2 (en) 2000-12-05 2003-09-02 Emu Unterwasserpumpen Gmbh Hydrodynamic machine
EP1347750A1 (en) 2000-12-15 2003-10-01 Pfizer Limited Treatment of male sexual dysfunction
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
JP2004523529A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチンレセプターアゴニスト
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
ATE341327T1 (de) 2001-02-28 2006-10-15 Merck & Co Inc Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
US7012084B2 (en) 2001-02-28 2006-03-14 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
MXPA03007785A (es) 2001-02-28 2003-12-08 Merck & Co Inc Derivados de piperidina acilados como agonistas del receptor de melanocortina 4.
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
CA2437594A1 (en) * 2001-03-02 2002-09-12 Graham S. Poindexter Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
EP1767525A1 (en) * 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
BR0209558A (pt) * 2001-05-11 2004-04-20 Biovitrum Ab Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
PT1392295E (pt) * 2001-05-15 2006-09-29 Hoffmann La Roche Derivados de oxazole substituidos por acidos carboxilicos para serem utilizados como activadores de rapp alfa e gama no tratamento de diabetes
EP1388537A1 (en) * 2001-05-15 2004-02-11 Taisho Pharmaceutical Co., Ltd Arginine derivatives
US6593362B2 (en) * 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
KR20040012956A (ko) * 2001-06-20 2004-02-11 화이자 프로덕츠 인코포레이티드 설폰산 유도체
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
AU2002320494B2 (en) 2001-07-18 2006-06-29 Merck Sharp & Dohme Corp. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
CN1781920A (zh) 2001-08-28 2006-06-07 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US20030158209A1 (en) * 2001-10-09 2003-08-21 Neurocrine Biosciences Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE60235249D1 (de) * 2001-10-22 2010-03-18 Pfizer Prod Inc Piperazinderivate mit ccr1-rezeptor-antagonistischer wirkung
MXPA04004458A (es) 2001-11-08 2005-06-08 Johnson & Johnson Novedosos derivados de 1,2,4-tiadiazol como moduladores del receptor de melanocortina.
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
PL369076A1 (en) 2001-12-21 2005-04-18 Taisho Pharmaceutical Co, Ltd. Piperazine derivative
JP2005527492A (ja) 2002-01-23 2005-09-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
US20030207814A1 (en) 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
US20040010010A1 (en) 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
EP1503761A1 (en) * 2002-05-10 2005-02-09 Neurocrine Biosciences, Inc. Substituted piperazines as melanocortin receptor ligands
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2004078716A1 (en) 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7709484B1 (en) * 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
US7834017B2 (en) * 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20090076029A1 (en) * 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity

Also Published As

Publication number Publication date
US7964601B2 (en) 2011-06-21
KR20060009285A (ko) 2006-01-31
EP1622618A1 (en) 2006-02-08
EA200501724A1 (ru) 2006-06-30
US7456184B2 (en) 2008-11-25
JP2006525369A (ja) 2006-11-09
US20080234289A1 (en) 2008-09-25
AU2004235792A1 (en) 2004-11-18
US20040224957A1 (en) 2004-11-11
EA012502B1 (ru) 2009-10-30
WO2004098602A1 (en) 2004-11-18
EP1622618A4 (en) 2008-08-27
CO5700752A2 (es) 2006-11-30
MXPA05011729A (es) 2006-02-13
AU2004235792A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
BRPI0410694A (pt) compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina
Kamchonwongpaisan et al. Inhibitors of multiple mutants of Plasmodium f alciparum dihydrofolate reductase and their antimalarial activities
BR0208455A (pt) Derivados de glutaramida substituìda com n-fenpropilciclopentila como inibidores de nep para a fsad
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
DE602004022404D1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
BRPI0601282A (pt) composição, e método de modificar a formação de hidrato de gás
NO20051207L (no) Proteinkinaseinhibitorer og anvendelser derav
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
BR0107807A (pt) Derivados de 1,3-dihidro-2h-indol-2-ona, processo para seu preparo e as composições farmacêuticas que os contêm
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
BRPI0606319A2 (pt) compostos farmacêuticos
NO20032253D0 (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
DE69732868D1 (de) Mittel gegen Juckreiz
MEP6208A (en) The combination of a serotonin reuptake inhibitor and a 5-ht¿2c? antagonist, inverse agonist or partial agonist
BR0111019A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
ES2179489T3 (es) Uso de tienopirimidinas como fungicidas.
BR0010348A (pt) Uso de antagonistas seletivos de receptor <244>~ 1b~-adrenérgico para aperfeiçoamento de disfunção sexual
BR0016952A (pt) Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
BR0109838A (pt) Metabólitos de agonista/antagonista de estrogênio
BR0307903A (pt) derivados de arilsulfona
EA200500984A1 (ru) Производные 3-замещённого-4-пиримидона
Reddy et al. Synthesis and pharmacological evaluation of N, N ‘-diarylguanidines as potent sodium channel blockers and anticonvulsant agents
NO20050937L (no) Indolin-derivater substituert i stilling 6, fremstilling og andvendelse derav som medikamenter

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.